Is long-term androgen suppression right for everyone with locally advanced prostate cancer?

摘要

In 1997, after a median follow-up of 45 months, the European Organisation for Research and Treatment of Cancer (EORTC) reported a randomised trial1 showing an overall survival benefitthat resulted in a change in practice from radiation therapy to radiation therapy plus 3 years of hormonal therapy for men with locally advanced prostate cancer. In this issue of The Lancet Oncology, their study is updated at a median follow-up of 9.1 years and the survival benefit remains-ie, there are men with locally advanced prostate cancer who live longer as a result of being given 3 years of hormonal therapy in conjunction with radiotherapy as oppposed to radiotherapy alone.